Skip to content

Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)

Observational Study in Diagnosed Patients Covid-19, Supported on an Outpatient Basis.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04402905
Acronym
COVID-PSL
Enrollment
450
Registered
2020-05-27
Start date
2020-06-15
Completion date
2020-08-15
Last updated
2021-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Infection

Brief summary

COVID-19 is an infection linked to a new coronavirus: SARS-CoV-2, which appeared in Wuhan in China at the end of 2019, and which has since spread around the world, responsible for a new major pandemic, which is upsetting the whole world. If severe respiratory disease is the form that constitutes the extreme gravity of the disease (mortality, with more than 170,000 deaths worldwide to date). However, there is a great heterogeneity of clinical forms with asymptomatic or symptomatic pauci forms, moderate forms, up to severe forms. Different symptoms may appear: fever, cough, asthenia, dyspnea, gastrointestinal forms, anosmia and / or ageusia, skin involvement, etc. Given the novelty of this infection, several questions remain: * What are all the symptoms that can be contracted by a COVID-19 patient? * Are there clinical forms not described? * What is the evolutionary profile, the healing time of this disease in patients treated on an outpatient basis? * What are the factors associated with a prolonged form of COVID-19 disease, including on an outpatient basis?

Detailed description

Most of the descriptive studies relating to COVID-19 relate to the severe forms of the disease managed in the hospital sector. Few data have been published on moderate forms, requiring no hospitalization, of strict outpatient management. These so-called moderate forms, however, constitute the majority of cases of COVID-19 (approximately 80%). In the Infectious and Tropical Diseases Department of Pitie Salpetriere, COVIDOM pilot site, at the beginning of March, during the intensification of the epidemic in France, a weekly telephone consultation was set up to take care of people tested for COVID + by PCR, or people not tested by PCR, or even tested with negative PCR but symptomatic and followed at home, suffering from moderate form of COVID-19, as well as their contact cases if they wished. Telemedicine is particularly suitable in this epidemic context, ensuring continuity of care, while limiting face-to-face consultations, thus reducing the risk of cross-contamination. Given the novelty of this infection, it is important to be able to best characterize these ambulatory forms, as well as their evolution, in order to manage these patients, and to offer primary care physicians a more detailed description of these forms. , which they are and will be called upon to take care of, general medicine being central to dealing with the epidemic.

Interventions

None listed

Sponsors

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \>18 years * COVID PCR + patient: Patient screened positive by PCR on nasopharyngeal swab * or COVID-like patient: Patient not screened, but considered COVID + because contact with a COVID PCR + person, and presenting symptoms suggestive of COVID-19 among: * Influenza-like illness (fever, body aches, arthralgia, etc.) * Respiratory form: dyspnea, cough, rhinitis * Gastrointestinal form: diarrhea, nausea, vomiting * Anosmia and / or ageusia * or patient COVID PCR-: If patient tested negative by PCR on nasopharyngeal swab, but showing signs suggestive of COVID-19.

Exclusion criteria

* Patient objecting to the use of their data for research purposes * Patient under justice or deprived of liberty.

Design outcomes

Primary

MeasureTime frameDescription
COVID-PSL Cohort3 monthsmeasure of the absence of symptoms to assess the rate of complete clinical recovery on day 30

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026